Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Trial Profile

An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Seborrhoeic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 08 Feb 2018 According to an Aclaris Therapeutics media release, data will be presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
    • 09 May 2017 According to an Aclaris Therapeutics media release, NDA for A-101 40% for the topical treatment of SK has been accepted by the FDA for review, based on the data from three phase III trials (see profile 257107 and 266887).The company also plans to submit a marketing authorization application (MAA) for A-101 40% for the treatment of SK in the European Union in the second half of 2017.
    • 01 Dec 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top